CA-CRED
Cred , the leading provider of crypto-backed lending with over $300 million in credit facilities and the Universal Protocol Alliance , creator of the Universal Protocol Platform, today announced that they will join the Board of the Blockchain Advocacy Coalition to provide education and support to state and federal legislators and regulators.
“We’re pleased to welcome Cred and the Universal Protocol Alliance to our Board,” said Ally Medina, Executive Director of BAC. “These pioneering blockchain organizations are at the cusp of innovation. By working closely with policymakers and regulators, our board members will help develop thoughtful policy initiatives that support innovation in the blockchain industry and benefit the U.S. economy.
Blockchain Advocacy Coalition has taken the time to build relationships in Sacramento with policymakers, regulatory bodies and office holders. California has half of the nation’s cryptocurrency and blockchain industry, a share that will increase as more positive legislation passes. The state is uniquely well positioned to lead the nation on regulation that supports blockchain innovation, and we are here to make sure it’s done right. Thoughtful legislation passed here can serve as a model for the federal government and other states.”
“We’re pleased to be working with BAC to help policymakers understand and advocate for crypto and blockchain friendly policies,” said Dan Schatt, Co-founder of Cred and the Universal Protocol Alliance. “Our mission is to offer a more equitable, transparent and inclusive set of financial services through blockchain technology. Helping Sacramento and Washington understand the policy implications with this new technology will ensure that it can be prioritized accordingly.”
“California has always been a place for innovation and opportunity, and SB 838 shows how we can use technology to increase consumer protection and help prevent cases of fraud,” said Senator Hertzberg (D-Van Nuys). “That it was signed into law is a great testament to the work being done around the state by folks like the Blockchain Advocacy Coalition to advance this rapidly growing technology.”
About the Blockchain Advocacy Coalition
The Blockchain Advocacy Coalition is committed to educating legislators and regulators about blockchain technology and advancing regulations that support innovation. BAC supports political advocacy that directly benefits the blockchain and cryptocurrency industry and allows its members to gain access and insight into local, state and federal level politics, and to connect with other businesses that share these values.
About Cred
Cred is a decentralized global lending platform that facilitates open access to credit anywhere and anytime. Founded by former PayPal financial technology veterans, Cred’s mission is to harness the power of blockchain to allow everyone to benefit from low-cost credit products. Cred’s LBA token is available in more than 180+ countries including the US. For more information, visit mycred.io or follow us on Twitter , Facebook and LinkedIn ,
About the Universal Protocol Alliance
Universal Protocol Alliance (UP) is a coalition of cryptocurrency companies and blockchain pioneers, the Universal Protocol Alliance seeks to accelerate the adoption of blockchain as a mainstream financial technology by making digital assets more accessible, secure and convenient to own. The Alliance consists of Uphold, Brave Software, Cred, Blockchain at Berkeley and FBG Capital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005933/en/
Contact:
Cred Meghan Gardler Director of Marketing meghan@mycred.io
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom